What to Look for When Selecting a CMO

A Practical Guide to CMO Evaluation for Biotech Companies

A few weeks ago, I wrote about what to do when your CMO isn't meeting expectations. The response told me something I already suspected — it's a widespread problem. But here's the thing: many of those difficult CMO relationships were set up to fail from the start. Not because the CMO was bad, but because the selection process was flawed.

Choosing a contract manufacturing organization is one of the highest-stakes decisions a biotech company will make. It directly impacts your timelines, your quality, your regulatory strategy, and ultimately your ability to get a therapy to patients. And yet, too often, the decision is driven by the wrong criteria.

Whether you're an early-stage company selecting your first manufacturing partner or a later-stage organization looking to scale or switch, here's what actually matters — and what to watch out for.

Stop Choosing on Price

Let's get the most common mistake out of the way first. Cost matters, obviously. But selecting a CMO primarily because they came in with the lowest bid is one of the fastest ways to end up in a painful situation twelve months from now.

A lower price often reflects trade-offs you can't see on a spreadsheet — thinner staffing, less experienced operators, slower turnaround on deviations, or fewer resources dedicated to your program. These things don't show up in the proposal. They show up when a batch fails and the investigation takes three months, or when your project manager is juggling six other sponsors and your emails sit unanswered for a week.

The better question isn't "who's cheapest?" It's "who gives me the best probability of success for this specific program?" That's a fundamentally different evaluation — and it's one that pays for itself many times over when things inevitably get complicated.

Beware the "I Know a Guy" Approach

This one is surprisingly common, especially in biotech where the industry is tight-knit and everyone has worked with everyone. A colleague recommends a CMO they had a great experience with. A board member has a relationship with a site's leadership team. A former coworker just took a business development role at a CDMO and reaches out with a compelling pitch.

Personal relationships and industry networks are valuable. They can open doors and accelerate conversations. But they should never be the primary basis for selecting a manufacturing partner. Your colleague's antibody program and your gene therapy program have fundamentally different requirements. The board member's relationship with the CEO doesn't tell you anything about the site's deviation closure rate or their capacity utilization.

When relationships drive the decision instead of informing it, you skip the rigorous evaluation that protects your program. And you often don't realize it until you're six months into a contract, wondering why the fit feels off.

Visit the Site. Actually Visit the Site.

It's remarkable how often companies commit to a CMO without stepping foot on the manufacturing floor. Due diligence questionnaires and capability presentations are useful, but they only tell you what a CMO wants you to see. An on-site audit tells you what's actually happening.

Walk the floor. Watch how operators interact with equipment and with each other. Look at the state of the facility — not the conference room they bring you to, but the warehouse, the gowning areas, the QC labs. Talk to the people who will actually work on your program, not just the business development team. Ask about their deviation and CAPA backlog. Ask what their current capacity looks like and how many programs are competing for time on the same equipment.

You'll learn more in a single site visit than in a dozen slide decks. And if a CMO is reluctant to host you before signing a contract, that itself is a data point worth paying attention to.

Evaluate the Intangibles

Beyond the technical capabilities and regulatory track record — which are table stakes — pay close attention to the things that don't fit neatly into an RFP scorecard.

How responsive are they during the proposal process? If it takes two weeks to get an answer to a straightforward question before you've signed a contract, imagine what it'll be like after. How transparent are they about their limitations? A CMO that tells you what they can't do is often more trustworthy than one that says yes to everything. How do they handle bad news? Ask for an example of a time something went wrong with a client program and how they managed it. The answer — or the reluctance to give one — will tell you a lot.

These "soft" factors aren't soft at all. They're the leading indicators of what your day-to-day working relationship will look like for the next several years.

Match the Partner to the Program

Not every CMO is the right CMO for your program — even if they're a great organization. A large, established CDMO with a stellar reputation in commercial monoclonal antibody manufacturing may not be the best fit for your Phase I cell therapy program. A smaller, more agile site might give you the attention and flexibility you need at an early stage but lack the infrastructure to scale with you into commercialization.

Think about where your program is today and where it's going. Consider whether you need a partner who can grow with you through multiple clinical phases and into commercial supply, or whether a phased approach with different partners at different stages makes more sense. Factor in the therapeutic modality, the complexity of your process, and the regulatory markets you're targeting. The best CMO selection decisions are program-specific, not one-size-fits-all.

Build the Evaluation Process You'll Thank Yourself for Later

If there's one takeaway from all of this, it's that CMO selection deserves the same rigor you'd apply to any other critical business decision. That means defining your evaluation criteria before you start talking to candidates. It means involving cross-functional stakeholders — not just supply chain, but quality, regulatory, CMC, and finance. It means documenting your rationale so that when someone asks in two years why you chose this partner, you have an answer that goes beyond "they had capacity" or "we knew someone there."

The upfront investment in a thorough, structured selection process is a fraction of the cost of unwinding a bad CMO relationship — in dollars, in time, and in regulatory risk. Get this decision right, and everything downstream gets easier. Rush it, and you'll spend the next several years managing the consequences.

Verant Consulting Group helps biotech companies navigate CMO selection, build manufacturing strategies, and set up outsourcing relationships for long-term success. If you're evaluating manufacturing partners and want a structured approach, let's connect.